Summary and Work Group Considerations

Lisa Grohskopf, MD, MPH
Influenza Division, CDC
Advisory Committee on Immunization Practices

February 27, 2019
Acknowledgments

Influenza Division
Elif Alyanak
Noreen Alabi
Lenee Blanton
Lynnette Brammer
Joe Bresee
Alicia Budd
Jessie Chung
Josh Doyle
Jill Ferdinands
Brendan Flannery
Alicia Fry
Dan Jernigan
Jackie Katz
Krista Kniss
Sankan Nyanseor
Manish Patel
Mark Thompson
Jerry Tokars
Tim Uyeki

Immunization Safety Office
Karen Broder
Frank Destefano
Penina Haber
Tom Shimabukuro

Immunization Services Division
Sam Graitcer
Andrew Kroger
Amy Parker Fiebelkorn
Jeanne Santoli
Influenza Vaccines for Young Children—Recent Licensure Changes

- **Afluria (IIV3) and Afluria Quadrivalent (IIV4, Seqirus):**
  - Age indication expanded from ≥5 years to ≥6 months in October 2018
  - Children aged 6 through 35 months receive smaller dose volume
    - 0.25mL, vs. 0.5mL for those aged ≥3 years

- **Fluzone Quadrivalent (IIV4, Sanofi Pasteur):**
  - 6 through 35 months previously received 0.25mL/dose
  - January 2019: FDA licensed 0.5mL/dose for all ages
    - Randomized non-inferiority trial of immunogenicity and safety of 0.25mL vs. 0.5mL in children aged 6 through 35 months presented to ACIP October 2018
  - Per labeling, 0.25mL or 0.5mL acceptable for 6 through 35 months
Influenza Vaccines for Young Children

- Less data and clinical experience with newer indications in this age group, particularly with concomitant receipt of other vaccines

- Five IIVs licensed for 6 through 35 months; dose volumes differ*:
  - *Fluarix Quadrivalent (IIV4, GSK)* 0.5mL
  - *Flulaval Quadrivalent (IIV4, ID Biomedical Corp/GSK)* 0.5 mL
  - *Fluzone Quadrivalent (IIV4, Sanofi Pasteur)* 0.25 mL or 0.5 mL
  - *Afluria (IIV3, Seqirus)* 0.25 mL
  - *Afluria Quadrivalent (IIV4, Seqirus)* 0.25 mL

*Dose volume for persons aged ≥3 years is 0.5mL for all IIVs
Vaccine Safety Datalink Study of IIV and SAB

- Discussion of differences between the current and previous studies
  - Matching
  - Study size/statistical power
  - Available vaccines (quadrivalent vs. trivalent)

- Results felt to be reassuring overall
Upcoming WG Activities

- **Development of 2019-20 ACIP Influenza statement ongoing**
  - Further discussion at June 2019 ACIP meeting
  - No substantial changes anticipated at this time
  - Anticipated publication August, 2019

- **Discussion of 2018-19 influenza vaccine effectiveness data**
  - No estimate of LAIV effectiveness anticipated this season from U.S. Flu VE Network

- **General influenza vaccine safety update anticipated for June 2019 meeting**
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.